Lauren Nowak
All proper. Good morning, and thanks for becoming a member of Cynata’s Scientific Trial Outcomes Webinar. Internet hosting this morning is Chair, Geoff Brooke; CEO, Dr. Kilian Kelly; and Chief Enterprise Officer, Dr. Mathias Kroll, who will take you thru the Section II acute graft-versus-host illness and Section III osteoarthritis trial outcomes. Then I am going to take questions on the finish of the presentation. [Operator Instructions] And lastly, as a reminder, this name is being recorded and will likely be out there on the investor hub very shortly.
I am going to now hand over to Geoff to formally begin.
Geoff Brooke
Thanks, Lauren. Geoff Brooke right here, I am the Chairman of Cynata. And as Lauren mentioned, we now have the CEO, Kilian, with us in addition to the Chief Enterprise Officer, Mathias. I am positive like all people else, we’re fairly — greater than fairly, we’re very disenchanted and fairly shocked by the outcomes that we have seen final week. After which we thought the perfect factor to do could be following the press launch is to do a webinar and lay all of it out and permit folks to ask questions.
So I am glad we have had so many individuals take up the supply. And once more, I simply can’t inform you how disenchanted we’re. Everyone has put their coronary heart and soul into this for numbers of years, not to mention shareholders’ funding in money, hard-earned money. So we fully perceive that. We have in reality, put money ourselves. So we perceive the frustration, not solely from an worker viewpoint, a clinician viewpoint, but in addition a shareholder viewpoint.
